Results 221 to 230 of about 26,125 (257)

Bispecific antibodies in cancer therapy

Current Opinion in Immunology, 1999
Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources

Discovery and development of bispecific antibodies

Protein Expression and Purification
Bispecific antibodies (BsAbs) represent a significant breakthrough in antibody-based therapeutics, offering the unique capability to engage two distinct targets simultaneously. BsAbs are expected to exert therapeutic effects that are unattainable with conventional antibody drugs. Specifically, they are being developed for use in intercellular bridging,
Tetsuya Wakabayashi, Taichi Kuramochi
openaire   +2 more sources

Introduction: bispecific antibodies

Journal of Immunological Methods, 2001
D M, Segal, G J, Weiner, L M, Weiner
openaire   +2 more sources

Bispecific antibodies rise again

Nature Reviews Drug Discovery, 2014
Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire   +2 more sources

How to Make Bispecific Antibodies

2000
This protocol describes the production of bispecific F(ab')2 antibody derivatives (BsAbs) by the linking of two Fab' fragments via their hinge region SH groups using the bifunctional crosslinker o-phenylenedimaleimide (o-PDM) as described by Glennie et al. (1,2). The procedure is illustrated in Fig. 1.
openaire   +2 more sources

Bispecific Antibody Therapy in Hemophilia

New England Journal of Medicine, 2017
Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire   +2 more sources

Bispecific Antibodies for Cancer Therapy

Immunotherapy, 2009
Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors.
openaire   +2 more sources

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody

Cell, 2022
Cheng Li, Wuqiang Zhan, Gaowei Hu
exaly  

Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy

Angewandte Chemie - International Edition, 2022
Zhimeng Wu
exaly  

A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

Molecular Therapy, 2021
Yulu Li, Yonghe Qi, Fengchao Wang
exaly